# EDGAR Filing Document

**Accession Number:** 0001615258
**File Stem:** 0001140361-25-021957
**Filing Date:** 2025-6
**Character Count:** 20856
**Document Hash:** e89e3e791c691934e9ef8795c51df539
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-25-021957.hdr.sgml**: 20250609

**ACCESSION NUMBER**: 0001140361-25-021957

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250609

**DATE AS OF CHANGE**: 20250609

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NATURES SUNSHINE PRODUCTS INC
- **CENTRAL INDEX KEY:** 0000275053
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 870327982
- **STATE OF INCORPORATION:** UT
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-32703
- **FILM NUMBER:** 251034519

**BUSINESS ADDRESS:**
- **STREET 1:** 2901 WEST BLUEGRASS BLVD.
- **STREET 2:** SUITE 100
- **CITY:** LEHI
- **STATE:** UT
- **ZIP:** 84043
- **BUSINESS PHONE:** (801) 341-7900

**MAIL ADDRESS:**
- **STREET 1:** 2901 WEST BLUEGRASS BLVD.
- **STREET 2:** SUITE 100
- **CITY:** LEHI
- **STATE:** UT
- **ZIP:** 84043

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMTEC INDUSTRIES INC
- **DATE OF NAME CHANGE:** 19821108
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
- **CENTRAL INDEX KEY:** 0001615258

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** F4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** BUILDING A
- **STREET 2:** NO. 1289 YISHAN ROAD
- **CITY:** SHANGHAI
- **STATE:** F4
- **ZIP:** 200233
- **BUSINESS PHONE:** 86 21 33987870

**MAIL ADDRESS:**
- **STREET 1:** BUILDING A
- **STREET 2:** NO. 1289 YISHAN ROAD
- **CITY:** SHANGHAI
- **STATE:** F4
- **ZIP:** 200233

## Exhibit 99.1

------

#### Exhibit 99.1

**DIRECTORS AND EXECUTIVE OFFICERS OF FOSUN PHARMA PERSONS CONTROLLING FOSUN PHARMA AND EXECUTIVE OFFICERS AND DIRECTORS OF OTHER PERSONS IN CONTROL OF FOSUN<br> PHARMA, FPUSA AND FOSUN INDUSTRIAL**

Fosun Pharma is a corporation organized under the laws of the People's Republic of China and listed on both the Shanghai Stock Exchange and The Stock Exchange of Hong Kong Limited with its principal business address at Building A, No. 1289 Yishan Road Shanghai, 200233, China. Fosun Pharma is an innovation-driven global healthcare company operating in the fields of pharmaceuticals, medical devices & diagnostics, and healthcare services. Through its strategic alliance with Sinopharm Group Co., Ltd., Fosun Pharma further extends its capabilities in pharmaceutical commerce.

The name, business address, present principal employment and citizenship of each director and executive officer of Fosun Pharma is set forth below.

#### Fosun Pharma

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Business address** | **Present Principal Employment** | **Citizenship** |
| Chen Yuqing | Building A, No. 1289 Yishan Road Shanghai, 200233, China | Executive Director, Chairman of the Board of Directors | China |
| Guan Xiaohui | Building A, No. 1289 Yishan Road Shanghai, 200233, China | Executive Director, Co-Chairman of the Board of Directors | China |
| Wen Deyong | Building A, No. 1289 Yishan Road Shanghai, 200233, China | Executive Director, Deputy Chairman of the Board of Directors, Chief Executive Officer | China |
| Wang Kexin | Building A, No. 1289 Yishan Road Shanghai, 200233, China | Executive Director <br>| China |
| Chen Qiyu | Building A, No. 1289 Yishan Road Shanghai, 200233, China | Non-executive Director | China |
| Xu Xiaoliang | Building A, No. 1289 Yishan Road Shanghai, 200233, China | Non-executive Director | China |
| Pan Donghui | Building A, No. 1289 Yishan Road Shanghai, 200233, China | Non-executive Director | Hong Kong, China |
| Wu Yifang | Building A, No. 1289 Yishan Road Shanghai, 200233, China | Non-executive Director | China |
| Li Ling | Building A, No. 1289 Yishan Road Shanghai, 200233, China | Independent Non-executive Director | China |
| Tang Guliang | Building A, No. 1289 Yishan Road Shanghai, 200233, China | Independent Non-executive Director | China |
| Wang Quandi | Building A, No. 1289 Yishan Road Shanghai, 200233, China | Independent Non-executive Director | China |
| Yu Tze Shan Hailson | Building A, No. 1289 Yishan Road Shanghai, 200233, China | Independent Non-executive Director | Hong Kong, China |

---

------

Fosun Pharma is a subsidiary of Fosun High Technology. Fosun High Technology is a corporation organized under the laws of the People's Republic of China with its principal business address at 16<sup>th</sup> Floor, Tower S1, 600 Zhongshan No. 2 Road (E), Shanghai, Huangpu District, Shanghai, China. Fosun High Technology is a subsidiary of Fosun International, which is a global innovation-driven consumer group which operates in four business segments, namely health, happiness, wealth and intelligent manufacturing.

The name, business address, present principal employment and citizenship of each director and executive officer of Fosun High Technology is set forth below.

#### Fosun High Technology

---

| | | |
|:---|:---|:---|
| **Name** | **Business Address** | **Present Principal Employment** |
| Chen Qiyu | 16th Floor, Tower S1, 600 Zhongshan No. 2 Road (E), Shanghai, Huangpu District, Shanghai, China | Chairman of the Board of Directors<br> China |
| Xu Xiaoliang | 16th Floor, Tower S1, 600 Zhongshan No. 2 Road (E), Shanghai, Huangpu District, Shanghai, China | Director and general manager<br> China |
| Gong Ping | 16th Floor, Tower S1, 600 Zhongshan No. 2 Road (E), Shanghai, Huangpu District, Shanghai, China | Director<br> China |

---

Fosun High Technology is a subsidiary of Fosun International. Fosun International is a corporation organized under the laws of Hong Kong with its principal business address at Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong. Fosun International's ordinary shares are listed on the main board of The Stock Exchange of Hong Kong Limited. Fosun International is a global innovation-driven consumer group which operates in four business segments, namely health, happiness, wealth and intelligent manufacturing.

The name, business address, present principal employment and citizenship of each director and executive officer of Fosun International is set forth below.

#### Fosun International

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Business Address** | **Present Principal Employment** | **Citizenship** |
| GUO Guangchang | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Executive Director and Chairman | Hong Kong, China |
| WANG Qunbin | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Executive Director and Co-Chairman | Hong Kong, China |
| CHEN Qiyu | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Executive Director and Co-Chief Executive Officer | China |
| XU Xiaoliang | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Executive Director and Co-Chief Executive Officer | China |
| GONG Ping | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Executive Director, Executive President and Chief Financial Officer | China |
| HUANG Zhen | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Executive Director and Executive President | China |
| PAN Donghui | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Executive Director, Executive President and Chief Human Resources Officer | Hong Kong, China |
| LI Shupei | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Non-executive Director | China |
| LI Fuhua | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Non-executive Director | China |
| ZHANG Shengman | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Independent Non-executive Director | Hong Kong, China |
| ZHANG Huaqiao | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Independent Non-executive Director | Hong Kong, China |
| David T. ZHANG | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Independent Non-executive Director | Hong Kong, China |
| LEE Kai-Fu | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Independent Non-executive Director | Republic of China |
| TSANG King Suen Katherine | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Independent Non-executive Director | Hong Kong, China |

---

------

Fosun International is a subsidiary of Fosun Holdings. Fosun Holdings is a corporation organized under the laws of Hong Kong with its principal business address at Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong. Fosun Holdings is principally engaged in investment holding.

The name, business address, present principal employment and citizenship of each director and executive officer of Fosun Holdings is set forth below.

#### Fosun Holdings

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Business Address** | **Present Principal Employment** | **Citizenship** |
| GUO Guangchang | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Director | Hong Kong, China |
| LAW Tsz Kwan Iris | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Director | Hong Kong, China |
| LI Tao | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Director | Hong Kong, China |

---

Fosun Holdings is a subsidiary of Fosun International Holdings. Fosun International Holdings is a corporation organized under the laws of British Virgin Islands with its principal business address at Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong. Fosun International Holdings is principally engaged in investment holding.

The name, business address, present principal employment and citizenship of each director and executive officer of Fosun International Holdings is set forth below.

#### Fosun International Holdings

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Business Address** | **Present Principal Employment** | **Citizenship** |
| GUO Guangchang | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Director | Hong Kong, China |
| LAW Tsz Kwan Iris | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Director | Hong Kong, China |
| LI Tao | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Director | Hong Kong, China |

---

------

Fosun International Holdings is owned 82.59% by Guangchang Guo with the remaining shares owned 17.41% by Qunbin Wang. Guangchang Guo's principal business address is Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong. He is a citizen of Hong Kong, China.

The name, business address, present principal employment and citizenship of each director and executive officer of FPUSA is set forth below.

#### Fosun Pharma USA Inc.

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Business address** | **Present Principal Employment** | **Citizenship** |
| Wu Yifang<br>| 104 Carnegie Center Drive, Suite 204, Princeton, New Jersey 08540 | Director | China |
| Zhang Wenjie | 104 Carnegie Center Drive, Suite 204, Princeton, New Jersey 08540 | Director | US Citizen |
| Feng Rongli | 104 Carnegie Center Drive, Suite 204, Princeton, New Jersey 08540 | Director | China |

---

FPUSA is a wholly owned subsidiary of Fosun Pharma. FPUSA is a Delaware corporation. Its principal place of business is 104 Carnegie Center Drive, Suite 204, Princeton, New Jersey 08540. FPUSA is a specialty pharmaceutical company.

The name, business address, present principal employment and citizenship of each director and executive officer of Fosun Industrial is set forth below.

#### Fosun Industrial

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Business address** | **Present Principal Employment** | **Citizenship** |
| Guan Xiaohui<br>| Room 1917, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong<br>| Chairman of the Board of Director<br>| China |
| LAW Tsz Kwan Iris<br>| Room 1917, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong<br>| Director | Hong Kong, China<br>|
| HUNG HSIU YING SAMMI<br>| Room 1917, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong<br>| Director | Hong Kong, China<br>|

---

Fosun Industrial is a wholly owned subsidiary of Fosun Pharma. The address of the principal business office for Fosun Industrial is Room 1917, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong. Fosun Industrial is a company incorporated under the laws of Hong Kong. Fosun Industrial is principally engaged in foreign investment, sale and consultancy service of Chinese and western medicine, diagnostic reagent, medical device products and relevant import and export business.

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 2)**

**NATURES SUNSHINE PRODUCTS INC**

*(Name of Issuer)*

**Common Stock, no par value**

*(Title of Class of Securities)*

**639027101**

*(CUSIP Number)*

**Yuqing Chen**<br>Shanghai Fosun Pharmaceutical (Group) Co<br>Ltd., No.1289 Yishan Road<br>Shanghai F4 200233<br>86 (21) 33987000

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**06/05/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **639027101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.** | Name of reporting person<br>**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CHINA** | Citizenship or place of organization<br>**CHINA** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**2918774.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**2918774.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2918774.00** | Aggregate amount beneficially owned by each reporting person<br>**2918774.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**15.9%** | Percent of class represented by amount in Row (11)<br>**15.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

| **CUSIP No.** | **639027101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Fosun Pharma USA Inc.** | Name of reporting person<br>**Fosun Pharma USA Inc.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**2854607.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**2854607.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2854607.00** | Aggregate amount beneficially owned by each reporting person<br>**2854607.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**15.6%** | Percent of class represented by amount in Row (11)<br>**15.6%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, no par value

**(b) Name of Issuer:**
NATURES SUNSHINE PRODUCTS INC

**(c) Address of Issuer's Principal Executive Offices:**
2901 West Bluegrass Blvd., Suite 100, Lehi, UT, 84043

This Amendment No. 2 to Schedule 13D amends the statement on Schedule 13D originally filed by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma") with the Securities and Exchange Commission ("SEC") on August 4, 2014, as amended by Amendment No. 1 filed with the SEC on September 2, 2014 (the "Original Schedule 13D," and together with Amendment No. 1, and this Amendment No. 2, the "Schedule 13D") relating to the common stock, no par value (the "Common Stock"), of Nature's Sunshine Products, Inc., a Utah corporation (the "Issuer"). In addition to other matters described herein, this Amendment No. 2 is being filed to report the transfer of 2,854,607 shares of Common Stock from Fosun Pharma to Fosun Pharma USA Inc. ("FPUSA"), a Delaware corporation and wholly-owned subsidiary of Fosun Pharma, and the inclusion of FPUSA as an additional Reporting Person as a result thereof.  Fosun Pharma and FPUSA are referred to herein collectively as the "Reporting Persons."

**Item 4. Purpose of Transaction**

Item 4 of the Schedule 13D is amended by adding the following information:

On June 5, 2025, Fosun Pharma contributed 2,854,607 shares of Common Stock to FPUSA.  The Reporting Persons may dispose or continue to hold all or a portion of the shares of Common Stock reported herein, subject to the Reporting Persons' evaluation of the Issuer's business, prospects and financial condition, the market for such securities, other opportunities available to the Reporting Persons, general economic conditions, stock market conditions and other factors.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The information from Items 7-11, inclusive, and Item 13 on the cover pages of this Schedule 13D is incorporated herein by reference. The beneficial ownership percentages used in this Schedule 13D are calculated based on a total of 18,350,801 shares of Common Stock outstanding as of April 18, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q, filed with the SEC on May 6, 2025.

**(b)**
The Reporting Persons have sole voting and dispositive power over an aggregate of 2,918,774 shares of Common Stock.  FPUSA directly owns 2,854,607 shares of Common Stock, and Fosun Industrial Co., Limited ("Fosun Industrial") directly owns 64,167 shares of Common Stock.  Fosun Pharma, as the parent of FPUSA and Fosun Industrial, indirectly beneficially owns the 2,918,774 shares of Common Stock directly owned by FPUSA and Fosun Industrial.

**(c)**
Except as described in Item 4 of this Schedule 13D, there have been no transactions in shares of Common Stock or any other securities of the Issuer by the Reporting Persons in the 60 days prior to the filing of this Amendment No. 2.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

**Signature:** /s/ Yuqing Chen

**Name/Title:** Yuqing Chen / Chairman

**Date:** 06/09/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Fosun Pharma USA Inc.

**Signature:** /s/ Yuqing Wang

**Name/Title:** Yuqing Wang / Chief Financial Officer

**Date:** 06/09/2025